サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1531041

肝細胞増殖因子（HGFs）市場：世界の産業分析、規模、シェア、成長、動向、2024年～2034年予測

Hepatocyte Growth Factors (HGFs) Market (Type: Phase III [Ongoing], Phase II [Approved], Phase II [Ongoing], Phase I, and Preclinical) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034

出版日
ページ情報
英文 141 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
肝細胞増殖因子（HGFs）市場：世界の産業分析、規模、シェア、成長、動向、2024年～2034年予測
出版日: 2024年06月18日
発行: Transparency Market Research
ページ情報: 英文 141 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

肝細胞増殖因子（HGFs）市場- 調査範囲

TMRの調査レポート「肝細胞増殖因子（HGFs）の世界市場」は、2024年から2034年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会についても調査しています。当レポートでは、2024年を基準年、2034年を予測年として、2018年から2034年までの世界の肝細胞増殖因子（HGFs）市場の収益と予測を提供しています。また、2024年から2034年までの世界の肝細胞増殖因子（HGFs）市場の複合年間成長率（CAGR %）も掲載しています。

本レポートは広範な調査を経て作成されています。1次調査では、アナリストが主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。2次調査では、主要企業の製品資料、アニュアルレポート、プレスリリース、関連資料などを参照し、肝細胞増殖因子（HGFs）市場を推察しました。

市場スナップショット
2023年の市場規模 7,030万米ドル
2034年の市場規模 1億4,100万米ドル
CAGR 6.5%

当レポートでは、世界の肝細胞増殖因子（HGFs）市場の競合情勢について調査しています。世界の肝細胞増殖因子（HGFs）市場で事業を展開する主要企業が特定され、各企業がさまざまな属性でプロファイルされています。企業概要、財務状況、最近の動向、SWOTなどが、本レポートで紹介されている世界の肝細胞増殖因子（HGFs）市場におけるプレイヤーの属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：市場

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場力学
  • 市場分析と予測、2020年～2034年

第5章 主要洞察

  • パイプライン分析
  • 主要製品・ブランド分析
  • 主要M&A
  • COVID-19による産業への影響

第6章 世界の市場分析と予測：タイプ別

  • イントロダクションと定義
  • 主な調査結果・発展
  • 市場金額予測：タイプ別、2020年～2034年
    • フェーズ III（進行中）
    • フェーズ II（承認済み）
    • フェーズ II（進行中）
    • フェーズI
    • 前臨床
  • 市場の魅力分析：タイプ別

第7章 世界の市場分析と予測：用途別

  • イントロダクションと定義
  • 主な調査結果・発展
  • 市場金額予測：用途別、2020年～2034年
    • 腫瘍学
    • 心臓血管
    • 中枢神経系
    • 血液疾患
  • 市場の魅力分析：用途別

第8章 世界の市場分析と予測：エンドユーザー別

  • イントロダクションと定義
  • 主な調査結果・発展
  • 市場金額予測：エンドユーザー別、2020年～2034年
    • 製薬・バイオテクノロジー企業
    • CMOとCDMO
    • 研究センターおよび学術機関
  • 市場の魅力分析：エンドユーザー別

第9章 世界の市場分析と予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別、2020年～2034年
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力分析：地域別

第10章 北米の市場分析と予測

第11章 欧州の市場分析と予測

第12章 アジア太平洋の市場分析と予測

第13章 ラテンアメリカの市場分析と予測

第14章 中東・アフリカの市場分析と予測

第15章 競合情勢

  • 市場企業- 競争マトリックス（企業階層と規模別）
  • 市場シェア分析：企業別（2023年）
  • 企業プロファイル
    • ViroMed
    • AnGes, Inc.
    • M3 Biotechnology, Inc.
    • AVEO Pharmaceuticals, Inc.
    • Molecular Partners AG
    • YooYoung Pharmaceutical Co., Ltd.
    • F-star Therapeutics Inc.
    • Galaxy Bio Tech
    • Kringle Pharma
図表

List of Tables

  • Table 01: Global Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Type, 2020-2034
  • Table 02: Global Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Application, 2020-2034
  • Table 03: Global Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by End-user, 2020-2034
  • Table 04: Global Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Region, 2020-2034
  • Table 05: North America Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Country, 2020-2034
  • Table 06: North America Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Type, 2020-2034
  • Table 07: North America Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Application, 2020-2034
  • Table 08: North America Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by End-user, 2020-2034
  • Table 09: Europe Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 10: Europe Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Type, 2020-2034
  • Table 11: Europe Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Application, 2020-2034
  • Table 12: Europe Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by End-user, 2020-2034
  • Table 13: Asia Pacific Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 14: Asia Pacific Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Type, 2020-2034
  • Table 15: Asia Pacific Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Application, 2020-2034
  • Table 16: Asia Pacific Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by End-user, 2020-2034
  • Table 17: Latin America Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 18: Latin America Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Type, 2020-2034
  • Table 19: Latin America Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Application, 2020-2034
  • Table 20: Latin America Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by End-user, 2020-2034
  • Table 21: Middle East & Africa Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 22: Middle East & Africa Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Type, 2020-2034
  • Table 23: Middle East & Africa Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Application, 2020-2034
  • Table 24: Middle East & Africa Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by End-user, 2020-2034

List of Figures

  • Figure 01: Global Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) and Distribution (%), by Region, 2023 and 2034
  • Figure 02: Global Hepatocyte Growth Factors (HGFs) Market Revenue (US$ Mn), by Type, 2023
  • Figure 03: Global Hepatocyte Growth Factors (HGFs) Market Value Share, by Type, 2023
  • Figure 04: Global Hepatocyte Growth Factors (HGFs) Market Revenue (US$ Mn), by Application, 2023
  • Figure 05: Global Hepatocyte Growth Factors (HGFs) Market Value Share, by Application, 2023
  • Figure 06: Global Hepatocyte Growth Factors (HGFs) Market Revenue (US$ Mn), by End-user, 2023
  • Figure 07: Global Hepatocyte Growth Factors (HGFs) Market Value Share, by End-user, 2023
  • Figure 08: Global Hepatocyte Growth Factors (HGFs) Market Value Share, by Region, 2023
  • Figure 09: Global Hepatocyte Growth Factors (HGFs) Market Value (US$ Mn) Forecast, 2020-2034
  • Figure 10: Global Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Type, 2023 and 2034
  • Figure 11: Global Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 12: Global Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Application, 2023 and 2034
  • Figure 13: Global Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Application, 2024-2034
  • Figure 14: Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 15: Global Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 16: Global Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Region, 2023 and 2034
  • Figure 17: Global Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 18: North America Hepatocyte Growth Factors (HGFs) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 19: North America Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 20: North America Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 21: North America Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Type, 2023 and 2034
  • Figure 22: North America Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Application, 2023 and 2034
  • Figure 23: North America Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 24: North America Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 25: North America Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Application, 2024-2034
  • Figure 26:North America Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 27: Europe Hepatocyte Growth Factors (HGFs) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 28: Europe Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 29: Europe Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 30: Europe Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Type, 2023 and 2034
  • Figure 31: Europe Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Application, 2023 and 2034
  • Figure 32: Europe Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 33: Europe Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 34: Europe Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Application, 2024-2034
  • Figure 35: Europe Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 36: Asia Pacific Hepatocyte Growth Factors (HGFs) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 37: Asia Pacific Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 38: Asia Pacific Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 39: Asia Pacific Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Type, 2023 and 2034
  • Figure 40: Asia Pacific Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Application, 2023 and 2034
  • Figure 41: Asia Pacific Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 42: Asia Pacific Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 43: Asia Pacific Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Application, 2024-2034
  • Figure 44: Asia Pacific Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 45: Latin America Hepatocyte Growth Factors (HGFs) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 46: Latin America Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 47: Latin America Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 48: Latin America Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Type, 2023 and 2034
  • Figure 49: Latin America Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Application, 2023 and 2034
  • Figure 50: Latin America Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 51: Latin America Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 52: Latin America Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Application, 2024-2034
  • Figure 53: Latin America Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 54: Middle East & Africa Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 55: Middle East & Africa Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 56: Middle East & Africa Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 57: Middle East & Africa Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Type, 2023 and 2034
  • Figure 58: Middle East & Africa Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Application, 2023 and 2034
  • Figure 59: Middle East & Africa Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 60: Middle East & Africa Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 61: Middle East & Africa Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Application, 2024-2034
  • Figure 62: Middle East & Africa Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by End-user, 2024-2034
目次
Product Code: TMRGL86224

Hepatocyte Growth Factors (HGFs) Market - Scope of Report

TMR's report on the global hepatocyte growth factors (HGFs) market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global hepatocyte growth factors (HGFs) market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global hepatocyte growth factors (HGFs) market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the hepatocyte growth factors (HGFs) market.

Market Snapshot
Market Value in 2023US$ 70.3 Mn
Market Value in 2034US$ 141 Mn
CAGR6.5%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global hepatocyte growth factors (HGFs) market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global hepatocyte growth factors (HGFs) market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global hepatocyte growth factors (HGFs) market.

The report delves into the competitive landscape of the global hepatocyte growth factors (HGFs) market. Key players operating in the global hepatocyte growth factors (HGFs) market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global hepatocyte growth factors (HGFs) market profiled in this report.

Key Questions Answered in Global hepatocyte growth factors (HGFs) Market Report:

  • What is the sales/revenue generated by hepatocyte growth factors (HGFs) across all regions during the forecast period?
  • What are the opportunities in the global hepatocyte growth factors (HGFs) market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Hepatocyte Growth Factors (HGFs) Market - Research Objectives and Research Approach

The comprehensive report on the global hepatocyte growth factors (HGFs) market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global hepatocyte growth factors (HGFs) market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global hepatocyte growth factors (HGFs) market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Hepatocyte Growth Factors (HGFs) Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Hepatocyte Growth Factors (HGFs) Market Analysis and Forecast, 2020-2034

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product /Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Hepatocyte Growth Factors (HGFs) Market Analysis and Forecast, by Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Type, 2020-2034
    • 6.3.1. Phase III (Ongoing)
    • 6.3.2. Phase II (Approved)
    • 6.3.3. Phase II (Ongoing)
    • 6.3.4. Phase I
    • 6.3.5. Preclinical
  • 6.4. Market Attractiveness Analysis, by Type

7. Global Hepatocyte Growth Factors (HGFs) Market Analysis and Forecast, by Application

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Application, 2020-2034
    • 7.3.1. Oncology
    • 7.3.2. Cardiovascular
    • 7.3.3. Central Nervous System
    • 7.3.4. Hematological Disorders
  • 7.4. Market Attractiveness Analysis, by Application

8. Global Hepatocyte Growth Factors (HGFs) Market Analysis and Forecast, by End-user

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by End-user, 2020-2034
    • 8.3.1. Pharmaceutical and Biotechnology Companies
    • 8.3.2. CMOs and CDMOs
    • 8.3.3. Research Centers & Academic Institutes
  • 8.4. Market Attractiveness Analysis, by End-user

9. Global Hepatocyte Growth Factors (HGFs) Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2020-2034
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Hepatocyte Growth Factors (HGFs) Market Analysis and Forecast

  • 10.1. Introduction
  • 10.2. Key Findings
  • 10.3. Market Value Forecast, by Type, 2020-2034
    • 10.3.1. Phase III (Ongoing)
    • 10.3.2. Phase II (Approved)
    • 10.3.3. Phase II (Ongoing)
    • 10.3.4. Phase I
    • 10.3.5. Preclinical
  • 10.4. Market Value Forecast, by Application, 2020-2034
    • 10.4.1. Oncology
    • 10.4.2. Cardiovascular
    • 10.4.3. Central Nervous System
    • 10.4.4. Hematological Disorders
  • 10.5. Market Value Forecast, by End-user, 2020-2034
    • 10.5.1. Pharmaceutical and Biotechnology Companies
    • 10.5.2. CMOs and CDMOs
    • 10.5.3. Research Centers & Academic Institutes
  • 10.6. Market Value Forecast, by Country, 2020-2034
    • 10.6.1. U.S.
    • 10.6.2. Canada
  • 10.7. Market Attractiveness Analysis
    • 10.7.1. By Type
    • 10.7.2. By Application
    • 10.7.3. By End-user
    • 10.7.4. By Country

11. Europe Hepatocyte Growth Factors (HGFs) Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. Key Findings
  • 11.3. Market Value Forecast, by Type, 2020-2034
    • 11.3.1. Phase III (Ongoing)
    • 11.3.2. Phase II (Approved)
    • 11.3.3. Phase II (Ongoing)
    • 11.3.4. Phase I
    • 11.3.5. Preclinical
  • 11.4. Market Value Forecast, by Application, 2020-2034
    • 11.4.1. Oncology
    • 11.4.2. Cardiovascular
    • 11.4.3. Central Nervous System
    • 11.4.4. Hematological Disorders
  • 11.5. Market Value Forecast, by End-user, 2020-2034
    • 11.5.1. Pharmaceutical and Biotechnology Companies
    • 11.5.2. CMOs and CDMOs
    • 11.5.3. Research Centers & Academic Institutes
  • 11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 11.6.1. Germany
    • 11.6.2. U.K.
    • 11.6.3. France
    • 11.6.4. Italy
    • 11.6.5. Spain
    • 11.6.6. Rest of Europe
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Type
    • 11.7.2. By Application
    • 11.7.3. By End-user
    • 11.7.4. By Country/Sub-region

12. Asia Pacific Hepatocyte Growth Factors (HGFs) Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Key Findings
  • 12.3. Market Value Forecast, by Type, 2020-2034
    • 12.3.1. Phase III (Ongoing)
    • 12.3.2. Phase II (Approved)
    • 12.3.3. Phase II (Ongoing)
    • 12.3.4. Phase I
    • 12.3.5. Preclinical
  • 12.4. Market Value Forecast, by Application, 2020-2034
    • 12.4.1. Oncology
    • 12.4.2. Cardiovascular
    • 12.4.3. Central Nervous System
    • 12.4.4. Hematological Disorders
  • 12.5. Market Value Forecast, by End-user, 2020-2034
    • 12.5.1. Pharmaceutical and Biotechnology Companies
    • 12.5.2. CMOs and CDMOs
    • 12.5.3. Research Centers & Academic Institutes
  • 12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 12.6.1. China
    • 12.6.2. Japan
    • 12.6.3. India
    • 12.6.4. Australia & New Zealand
    • 12.6.5. Rest of Asia Pacific
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Type
    • 12.7.2. By Application
    • 12.7.3. By End-user
    • 12.7.4. By Country/Sub-region

13. Latin America Hepatocyte Growth Factors (HGFs) Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Key Findings
  • 13.3. Market Value Forecast, by Type, 2020-2034
    • 13.3.1. Phase III (Ongoing)
    • 13.3.2. Phase II (Approved)
    • 13.3.3. Phase II (Ongoing)
    • 13.3.4. Phase I
    • 13.3.5. Preclinical
  • 13.4. Market Value Forecast, by Application, 2020-2034
    • 13.4.1. Oncology
    • 13.4.2. Cardiovascular
    • 13.4.3. Central Nervous System
    • 13.4.4. Hematological Disorders
  • 13.5. Market Value Forecast, by End-user, 2020-2034
    • 13.5.1. Pharmaceutical and Biotechnology Companies
    • 13.5.2. CMOs and CDMOs
    • 13.5.3. Research Centers & Academic Institutes
  • 13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 13.6.1. Brazil
    • 13.6.2. Mexico
    • 13.6.3. Rest of Latin America
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Type
    • 13.7.2. By Application
    • 13.7.3. By End-user
    • 13.7.4. By Country/Sub-region

14. Middle East & Africa Hepatocyte Growth Factors (HGFs) Market Analysis and Forecast

  • 14.1. Introduction
  • 14.2. Key Findings
  • 14.3. Market Value Forecast, by Type, 2020-2034
    • 14.3.1. Phase III (Ongoing)
    • 14.3.2. Phase II (Approved)
    • 14.3.3. Phase II (Ongoing)
    • 14.3.4. Phase I
    • 14.3.5. Preclinical
  • 14.4. Market Value Forecast, by Application, 2020-2034
    • 14.4.1. Oncology
    • 14.4.2. Cardiovascular
    • 14.4.3. Central Nervous System
    • 14.4.4. Hematological Disorders
  • 14.5. Market Value Forecast, by End-user, 2020-2034
    • 14.5.1. Pharmaceutical and Biotechnology Companies
    • 14.5.2. CMOs and CDMOs
    • 14.5.3. Research Centers & Academic Institutes
  • 14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 14.6.1. GCC Countries
    • 14.6.2. South Africa
    • 14.6.3. Rest of Middle East & Africa
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Type
    • 14.7.2. By Application
    • 14.7.3. By End-user
    • 14.7.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
  • 15.2. Market Share Analysis, by Company (2023)
  • 15.3. Company Profiles
    • 15.3.1. ViroMed
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Product Portfolio
      • 15.3.1.3. SWOT Analysis
      • 15.3.1.4. Financial Overview
      • 15.3.1.5. Strategic Overview
    • 15.3.2. AnGes, Inc.
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Product Portfolio
      • 15.3.2.3. SWOT Analysis
      • 15.3.2.4. Financial Overview
      • 15.3.2.5. Strategic Overview
    • 15.3.3. M3 Biotechnology, Inc.
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Product Portfolio
      • 15.3.3.3. SWOT Analysis
      • 15.3.3.4. Financial Overview
      • 15.3.3.5. Strategic Overview
    • 15.3.4. AVEO Pharmaceuticals, Inc.
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Product Portfolio
      • 15.3.4.3. SWOT Analysis
      • 15.3.4.4. Financial Overview
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Molecular Partners AG
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Product Portfolio
      • 15.3.5.3. SWOT Analysis
      • 15.3.5.4. Financial Overview
      • 15.3.5.5. Strategic Overview
    • 15.3.6. YooYoung Pharmaceutical Co., Ltd.
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Product Portfolio
      • 15.3.6.3. SWOT Analysis
      • 15.3.6.4. Financial Overview
      • 15.3.6.5. Strategic Overview
    • 15.3.7. F-star Therapeutics Inc.
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Product Portfolio
      • 15.3.7.3. SWOT Analysis
      • 15.3.7.4. Financial Overview
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Galaxy Bio Tech
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Product Portfolio
      • 15.3.8.3. SWOT Analysis
      • 15.3.8.4. Financial Overview
      • 15.3.8.5. Strategic Overview
    • 15.3.9. Kringle Pharma
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Product Portfolio
      • 15.3.9.3. SWOT Analysis
      • 15.3.9.4. Financial Overview
      • 15.3.9.5. Strategic Overview